Analysts expect that Spero Therapeutics Inc (NASDAQ:SPRO) will announce earnings of ($1.15) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($1.37) and the highest is ($0.95). Spero Therapeutics reported earnings per share of ($0.74) during the same quarter last year, which indicates a negative year over year growth rate of 55.4%. The company is expected to report its next quarterly earnings results on Thursday, August 13th.
According to Zacks, analysts expect that Spero Therapeutics will report full-year earnings of ($4.09) per share for the current year, with EPS estimates ranging from ($4.69) to ($3.71). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.67) per share, with EPS estimates ranging from ($4.76) to ($2.91). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.22) earnings per share for the quarter, topping the consensus estimate of ($1.35) by $0.13. The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $3.36 million. Spero Therapeutics had a negative net margin of 654.03% and a negative return on equity of 88.22%.
Spero Therapeutics stock traded up $0.54 during mid-day trading on Friday, hitting $12.50. The company’s stock had a trading volume of 221,761 shares, compared to its average volume of 240,055. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.31 and a current ratio of 4.31. The business has a 50 day moving average price of $9.82 and a 200-day moving average price of $9.69. Spero Therapeutics has a 12 month low of $5.25 and a 12 month high of $14.38.
A number of hedge funds have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC raised its stake in Spero Therapeutics by 7.4% in the first quarter. Janney Montgomery Scott LLC now owns 14,500 shares of the company’s stock worth $117,000 after buying an additional 1,000 shares in the last quarter. Rhumbline Advisers raised its stake in Spero Therapeutics by 6.7% in the first quarter. Rhumbline Advisers now owns 16,417 shares of the company’s stock worth $133,000 after buying an additional 1,030 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in Spero Therapeutics by 37.3% in the first quarter. BNP Paribas Arbitrage SA now owns 3,834 shares of the company’s stock worth $31,000 after buying an additional 1,042 shares in the last quarter. Citigroup Inc. raised its stake in Spero Therapeutics by 68.6% in the first quarter. Citigroup Inc. now owns 4,042 shares of the company’s stock worth $33,000 after buying an additional 1,644 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Spero Therapeutics by 11.4% in the first quarter. New York State Common Retirement Fund now owns 18,429 shares of the company’s stock worth $149,000 after buying an additional 1,879 shares in the last quarter. 48.09% of the stock is owned by institutional investors.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease.
Recommended Story: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.